[go: up one dir, main page]

AU2139388A - Glycosaminoglycane for the treatment of diabetic microangiopathy - Google Patents

Glycosaminoglycane for the treatment of diabetic microangiopathy

Info

Publication number
AU2139388A
AU2139388A AU21393/88A AU2139388A AU2139388A AU 2139388 A AU2139388 A AU 2139388A AU 21393/88 A AU21393/88 A AU 21393/88A AU 2139388 A AU2139388 A AU 2139388A AU 2139388 A AU2139388 A AU 2139388A
Authority
AU
Australia
Prior art keywords
diabetic microangiopathy
glycosaminoglycane
treatment
prophylaxy
glycosaminoglycanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21393/88A
Inventor
Roland Reiner
Helgard Reiner-Struschka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2139388A publication Critical patent/AU2139388A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

It has been discovered that glycosaminoglycanes such as chondroitin sulphate are highly effective as therapeutic and prophylactic agents against diabetic microangiopathy (retinopathy, nephropathy and other manifestations related to capillary pathologies). Glycosaminoglycanes may be used as oral, parenteral or topic preparations for the therapy and prophylaxy of diabetic microangiopathy. Because of its effectiveness when orally administered and of its remarkable compatibility, the oral administration of chondroitin sulphate is particularly advantageous, since this compound is specially suitable for the long term therapy and prophylaxy of diabetic microangiopathy.
AU21393/88A 1988-06-27 1988-08-18 Glycosaminoglycane for the treatment of diabetic microangiopathy Abandoned AU2139388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2442/88 1988-06-27
CH244288 1988-06-27

Publications (1)

Publication Number Publication Date
AU2139388A true AU2139388A (en) 1990-01-23

Family

ID=4233917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21393/88A Abandoned AU2139388A (en) 1988-06-27 1988-08-18 Glycosaminoglycane for the treatment of diabetic microangiopathy

Country Status (6)

Country Link
EP (1) EP0380501B1 (en)
JP (1) JPH03500168A (en)
AT (1) ATE81462T1 (en)
AU (1) AU2139388A (en)
DE (1) DE3875349D1 (en)
WO (1) WO1990000058A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (en) * 1991-05-17 1994-10-25 Alfa Wassermann Spa USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY.
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
IT1270095B (en) * 1994-09-28 1997-04-28 Ibsa Inst Biochimique Sa THERAPEUTIC COMPOSITIONS OF CHONDROITIN SULPHATE IN THE FORM OF ORAL ADMINISTRABLE GEL
JP2001511153A (en) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン Compositions and methods for prevention and treatment of vascular degenerative diseases
WO1999004801A1 (en) * 1997-07-28 1999-02-04 Rijks Universiteit Leiden Use of sulfated glycosaminoglycans for treating of retinopathy
DE19747195A1 (en) * 1997-10-24 1999-04-29 Knoll Ag Compositions for treating diabetic retinopathy
CA2361268C (en) 1999-02-01 2014-06-10 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4554910B2 (en) * 2002-11-01 2010-09-29 生化学工業株式会社 Hypoglycemic agent
JP2009234916A (en) * 2006-07-24 2009-10-15 Stelic Institute Of Regenerative Medicine Insulin resistance reducer based on chondroitin sulfate proteoglycan accumulation regulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544136B2 (en) * 1986-05-23 1996-10-16 第一製薬株式会社 Angiogenesis inhibitor and antitumor agent containing sulfated polysaccharide DS4152
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
JP2667441B2 (en) * 1988-05-18 1997-10-27 生化学工業株式会社 Vascular endothelial cell growth inhibitor

Also Published As

Publication number Publication date
DE3875349D1 (en) 1992-11-19
EP0380501B1 (en) 1992-10-14
ATE81462T1 (en) 1992-10-15
JPH03500168A (en) 1991-01-17
WO1990000058A1 (en) 1990-01-11
EP0380501A1 (en) 1990-08-08

Similar Documents

Publication Publication Date Title
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
IT1252868B (en) ANTI-PHALALGIC PHARMACEUTICAL COMPOSITION FOR ENDONASAL ADMINISTRATION, PROCEDURE TO PREPARE IT AND ITS THERAPEUTIC USE
MY132705A (en) Novel compounds with analgesic effect
AU6444786A (en) The use of 2-amino-3-benzoylbenzeneacetic acids and derivatives in pharmaceutical preparations
MY119403A (en) Novel compounds with analgesic effect.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
MY114389A (en) Aqueous risperidone formulations
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
SG54210A1 (en) Oral composition for the treatment of bowel inflammatory bowel diseases
ATE282418T1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
ZA948669B (en) New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
NO307687B1 (en) Use of riluzole in the manufacture of medications for the treatment of neuro-AIDS
AU1890295A (en) Piperidines and pyrrolidines
AU2139388A (en) Glycosaminoglycane for the treatment of diabetic microangiopathy
AU2749288A (en) Use of polysulfated heparins
AU2861389A (en) Disubstituted pyridines
DE69827295D1 (en) COMBINATION OF A MEDICINE BLOCKING RETINOIC ACID METABOLISM AND A TOCOPHEROL
PH27446A (en) Compound with gastric acid inhibitory effect
AU1956092A (en) Pharmaceutical agent for treatment of withdrawal symptoms
YU13599A (en) Use of pharmaceutical composition for preparation of medicament in a gel form
AU3709289A (en) Strontium salt
AU7937691A (en) Parathyroid hypertensive factor
ES2170377T3 (en) COMPOSITION CONTAINING QUITOSANA.
AU4040195A (en) Topical composition containing penciclovir